NKGen Biotech, Inc. (NKGN)
OTCMKTS
· Delayed Price · Currency is USD
0.1223
+0.0104 (9.29%)
Apr 23, 2025, 1:47 PM EDT
NKGen Biotech Employees
NKGen Biotech had 63 employees as of December 31, 2023.
Employees
63
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$769,492
Market Cap
5.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 63 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| SS Innovations International | 378 |
| Endo Inc. | 3,116 |
| Elite Pharmaceuticals | 64 |
| Northwest Biotherapeutics | 25 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| American Oncology Network | 1,914 |
| Longduoduo Company | 49 |
NKGen Biotech News
- 9 days ago - NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition - Benzinga
- 9 days ago - NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition - GlobeNewsWire
- 16 days ago - NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) - GlobeNewsWire
- 4 weeks ago - NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) - GlobeNewsWire
- 7 weeks ago - NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented - GlobeNewsWire
- 7 weeks ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire
- 2 months ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire
- 2 months ago - NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site - GlobeNewsWire